{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:42:21Z","timestamp":1789864941357,"version":"4.0.1"},"reference-count":70,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006416","name":"Universidade Estadual de Campinas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"State of Sao Paulo Research Foundation","doi-asserted-by":"publisher","award":["2022\/06532-3"],"award-info":[{"award-number":["2022\/06532-3"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.clinthera.2025.07.012","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T11:09:20Z","timestamp":1754737760000},"page":"904-917","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Genetic Polymorphisms as Treatment Biomarkers for Gynecological Malignancies Treated With Carboplatin and Paclitaxel: A Systematic Review"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9692-6099","authenticated-orcid":false,"given":"Nadine de Godoy","family":"Torso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmim Gabriele","family":"Matos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovana Fernanda Santos","family":"Fidelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Dagli-Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00edlia Berlofa","family":"Visacri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eder de Carvalho","family":"Pincinato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jefman Efendi","family":"Marzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baharuddin","family":"Baharuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo Caleb J.L.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4927-7022","authenticated-orcid":false,"given":"Patricia","family":"Moriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.07.012_bib0001","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0020-7292(00)90001-8","article-title":"FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology","volume":"70","author":"Benedet","year":"2000","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0002","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0003","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.61","article-title":"Ovarian cancer","volume":"2","author":"Matulonis","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0004","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ogc.2018.09.008","article-title":"Vulvar cancer","volume":"46","author":"Weinberg","year":"2019","journal-title":"Obstet Gynecol Clin North Am"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0005","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41572-021-00324-8","article-title":"Endometrial cancer","volume":"7","author":"Makker","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0006","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"du Bois","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0007","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0008","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1200\/JCO.2000.18.17.3084","article-title":"Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer","volume":"18","author":"Neijt","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0009","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel\u2013carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0010","first-page":"4163","article-title":"Reporting of paclitaxel-induced peripheral neuropathy symptoms to clinicians among women with breast cancer: a qualitative study","volume":"28","author":"Salgado","year":"2020","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0011","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/jps.21169","article-title":"ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel","volume":"97","author":"Gr\u00e9en","year":"2008","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0012","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/annonc\/mdx491","article-title":"Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician reported incidence and severity of neurotoxicity in the ICON7 trial","volume":"28","author":"Park","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0013","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3390\/genes13020311","article-title":"Pharmacogenetics of drugs used in the treatment of cancers","volume":"13","author":"Franczyk","year":"2022","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0014","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"The BMJ"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0015","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0016","unstructured":"Wells G, Shea B, O\u2019Connell D, et al. The Newcastle\u2013Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analysis|Request PDF. 2012. Accessed May 12, 2024. https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0017","first-page":"553","article-title":"Identification of CYP2C8 gene polymorphisms in Korean patients with epithelial ovarian cancer and their association with effect and toxicity of anticancer drug","volume":"49","author":"Hwang","year":"2006","journal-title":"Korean J Obstet Gynecol"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0018","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00404-019-05197-7","article-title":"Impact of gene polymorphisms on the systemic toxicity to paclitaxel\/carboplatin chemotherapy for treatment of gynecologic cancers","volume":"300","author":"de Castro","year":"2019","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0019","doi-asserted-by":"crossref","first-page":"29789","DOI":"10.18632\/oncotarget.25712","article-title":"GSTP1 rs1695 is associated with both hematological toxicity and prognosis of ovarian cancer treated with paclitaxel plus carboplatin combination chemotherapy: a comprehensive analysis using targeted resequencing of 100 pharmacogenes","volume":"9","author":"Yoshihama","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0020","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ygyno.2009.11.011","article-title":"The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer","volume":"117","author":"Steffensen","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0021","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/cts.12937","article-title":"GSTP1 and ABCB1 polymorphisms predicting toxicities and clinical management on carboplatin and paclitaxel-based chemotherapy in ovarian cancer","volume":"14","author":"Ferracini","year":"2021","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0022","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1158\/1078-0432.CCR-15-0632","article-title":"Genome-wide analysis identifies novel loci associated with ovarian cancer outcomes: findings from the ovarian cancer association consortium","volume":"21","author":"Johnatty","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0023","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/bcpt.12997","article-title":"ABCB1 variation affects myelosuppression, progression-free survival and overall survival in paclitaxel\/carboplatin-treated ovarian cancer patients","volume":"123","author":"Bj\u00f6rn","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0024","doi-asserted-by":"crossref","first-page":"6365","DOI":"10.18632\/oncotarget.7047","article-title":"Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer","volume":"7","author":"French","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0025","doi-asserted-by":"crossref","first-page":"871","DOI":"10.3109\/0284186X.2012.707787","article-title":"GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients","volume":"52","author":"Bergmann","year":"2013","journal-title":"Acta Oncol (Madr)"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0026","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.lfs.2015.11.011","article-title":"Genetic variations in the PI3K\/AKT pathway predict platinum-based neoadjuvant chemotherapeutic sensitivity in squamous cervical cancer","volume":"143","author":"Guo","year":"2015","journal-title":"Life Sci"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0027","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1158\/1078-0432.CCR-11-0724","article-title":"Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients","volume":"17","author":"Huang","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0028","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/emm.2006.38","article-title":"Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer","volume":"38","author":"Kang","year":"2006","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0029","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4149\/neo_2018_170322N205","article-title":"USF1 gene polymorphisms may associate with the efficacy and safety of chemotherapy based on paclitaxel and prognosis in the treatment of ovarian cancer","volume":"65","author":"Ye","year":"2018","journal-title":"Neoplasma"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0030","first-page":"209","article-title":"Differences in efficacy and toxicity in relation to genetic polymorphisms of the cytochrome P450 2C8 gene after chemotherapy in epithelial ovarian cancer","volume":"40","author":"Park","year":"2019","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0031","doi-asserted-by":"crossref","first-page":"314","DOI":"10.4103\/ijph.ijph_809_23","article-title":"Genetic variations affect chemotherapy outcomes: a role of the spindle-assembly checkpoint","volume":"68","author":"Sarkar","year":"2024","journal-title":"Indian J Public Health"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0032","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1002\/jps.22680","article-title":"Impact of CYP3A5*3 and CYP2C8-HapC on paclitaxel\/carboplatin-induced myelosuppression in patients with ovarian cancer","volume":"100","author":"Gr\u00e9en","year":"2011","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0033","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1742-7843.2011.00802.x","article-title":"Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 93 women with ovarian cancer","volume":"110","author":"Bergmann","year":"2012","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0034","doi-asserted-by":"crossref","first-page":"5594","DOI":"10.1158\/1078-0432.CCR-08-0606","article-title":"ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel\/carboplatin chemotherapy","volume":"14","author":"Johnatty","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0035","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/jcph.587","article-title":"Genetic variation of CYP3A5 influences paclitaxel\/carboplatin-induced toxicity in Chinese epithelial ovarian cancer patients","volume":"56","author":"Hu","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0036","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s00228-020-02934-9","article-title":"ABCB1 and ERCC1 gene polymorphisms are associated with nephro- and hepatotoxicity to carboplatin\/paclitaxel-based chemotherapy in patients with gynecologic cancers","volume":"76","author":"da Costa Junior","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0037","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0038","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole-genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2025.07.012_bib69","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s002800050723","article-title":"Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin","volume":"41","author":"Cassidy","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clinthera.2025.07.012_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/mpo.1154","article-title":"Response evaluation criteria in solid tumors (RECIST): new guidelines","volume":"37","author":"Tsuchida","year":"2001","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0039","doi-asserted-by":"crossref","first-page":"6547","DOI":"10.1002\/sim.3420","article-title":"Methodological quality of pharmacogenetic studies: issues of concern","volume":"27","author":"Jorgensen","year":"2008","journal-title":"Stat Med"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0040","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1742-7843.2008.00351.x","article-title":"Pharmacogenetic studies of paclitaxel in the treatment of ovarian cancer","volume":"104","author":"Gr\u00e9en","year":"2008","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0041","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s11033-023-08915-2","article-title":"Genetic polymorphisms as potential pharmacogenetic biomarkers for platinum-based chemotherapy in non-small cell lung cancer","volume":"51","author":"Sito","year":"2024","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0042","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2018.00507","article-title":"Exploring the impact of single-nucleotide polymorphisms on translation","volume":"9","author":"Robert","year":"2018","journal-title":"Front Genet"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0043","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/sj.tpj.6500413","article-title":"ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research","volume":"7","author":"Leschziner","year":"2007","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0044","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0045","article-title":"The drug-resistance mechanisms of five platinum-based antitumor agents","volume":"11","author":"Zhou","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0046","doi-asserted-by":"crossref","first-page":"3","DOI":"10.31557\/APJCP.2021.22.1.3","article-title":"Prognostic value of two polymorphisms, rs1045642 and rs1128503, in ABCB1 following taxane-based chemotherapy: a meta-analysis","volume":"22","author":"Chen","year":"2021","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0047","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/0008-5472.CAN-13-2064","article-title":"Synonymous polymorphisms alter transporter specificity and protein stability in a stable epithelial monolayer","volume":"74","author":"Fung","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0048","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","article-title":"Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo","volume":"97","author":"Hoffmeyer","year":"2000","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0049","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/cas.12560","article-title":"ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy","volume":"106","author":"Kim","year":"2015","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0050","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.clpt.2006.02.003","article-title":"Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms","volume":"79","author":"Tran","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0051","article-title":"Towards a mechanistic understanding of axon transport and endocytic changes underlying paclitaxel-induced peripheral neuropathy","volume":"359","author":"Ji-Eun Shin","year":"2023","journal-title":"Exp Neurol"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0052","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00280-016-2976-z","article-title":"Platinum-based drugs: past, present and future","volume":"77","author":"Dilruba","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0053","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0054","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/cpt.1830","article-title":"Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2C9 and nonsteroidal anti-inflammatory drugs","volume":"108","author":"Theken","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0055","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.2217\/pgs.09.82","article-title":"Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies","volume":"10","author":"Daily","year":"2009","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0056","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1124\/pr.115.011411","article-title":"Role of cytochrome P450 2C8 in drug metabolism and interactions","volume":"68","author":"Backman","year":"2016","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0057","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2174\/138920009790711832","article-title":"Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms","volume":"10","author":"Lai","year":"2009","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0058","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1124\/dmd.114.058834","article-title":"Expression of hepatic drug-metabolizing cytochrome P450 enzymes and their intercorrelations: a meta-analysis","volume":"42","author":"Achour","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0059","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/FPC.0b013e32805b72c1","article-title":"CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population","volume":"17","author":"Saito","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0060","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.3390\/ijms20174136","article-title":"New insights into mechanisms of cisplatin resistance: from tumor cell to microenvironment","volume":"20","author":"Chen","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0061","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1158\/1535-7163.MCT-08-0250","article-title":"Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin","volume":"7","author":"Peklak-Scott","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0062","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1006\/bbrc.1997.6777","article-title":"Active site architecture of polymorphic forms of human glutathione S-transferase P1-1 accounts for their enantioselectivity and disparate activity in the glutathione conjugation of 7b,8a-dihydroxy-9a, 10a-oxy-7,8,9,10-tetrahydrobenzo(a)pyrene","volume":"235","author":"Hu","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0063","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2288-14-45","article-title":"Newcastle-Ottawa scale: comparing reviewers\u2019 to authors\u2019 assessments","volume":"14","author":"Lo","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0064","doi-asserted-by":"crossref","first-page":"9812","DOI":"10.1038\/srep09812","article-title":"Genomic ancestry and ethnoracial self-classification based on 5,871 community-dwelling Brazilians (The Epigen Initiative)","volume":"5","author":"Fernanda Lima-Costa","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0065","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2217\/pgs-2021-0128","article-title":"Pharmacogenetics research in Brazil: a systematic review","volume":"23","author":"Torres-Loureiro","year":"2022","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0066","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1111\/cts.13110","article-title":"Applying an equity lens to pharmacogenetic research and translation to under-represented populations","volume":"14","author":"Luczak","year":"2021","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0067","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.tips.2005.02.008","article-title":"Pharmacogenomics in admixed populations","volume":"26","author":"Suarez-Kurtz","year":"2005","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.clinthera.2025.07.012_bib0068","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jclinepi.2008.12.004","article-title":"Strengthening the reporting of genetic association studies (STREGA)-an extension of the strengthening the reporting of observational studies in epidemiology (STROBE) statement","volume":"62","author":"Little","year":"2009","journal-title":"J Clin Epidemiol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825002498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825002498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:22:27Z","timestamp":1777490547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825002498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":70,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0149291825002498"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.07.012","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic Polymorphisms as Treatment Biomarkers for Gynecological Malignancies Treated With Carboplatin and Paclitaxel: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}